Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,366,595
  • Shares Outstanding, K 82,806
  • Annual Sales, $ 377,710 K
  • Annual Income, $ -132,530 K
  • EBIT $ -183 M
  • EBITDA $ -192 M
  • 60-Month Beta 1.90
  • Price/Sales 6.34
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 68.55% ( +5.06%)
  • Historical Volatility 87.22%
  • IV Percentile 38%
  • IV Rank 52.91%
  • IV High 98.15% on 11/04/24
  • IV Low 35.30% on 05/31/24
  • Put/Call Vol Ratio 0.68
  • Today's Volume 744
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 17,484
  • Open Int (30-Day) 15,864

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.16
  • Number of Estimates 8
  • High Estimate -0.88
  • Low Estimate -1.37
  • Prior Year 1.73
  • Growth Rate Est. (year over year) -167.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.18 +14.11%
on 11/22/24
31.00 -14.68%
on 12/10/24
+2.33 (+9.66%)
since 11/18/24
3-Month
21.14 +25.15%
on 10/24/24
32.29 -18.09%
on 11/11/24
+0.94 (+3.68%)
since 09/18/24
52-Week
20.84 +26.92%
on 04/25/24
49.50 -46.57%
on 02/27/24
-1.00 (-3.64%)
since 12/18/23

Most Recent Stories

More News
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEAM : 26.45 (-7.45%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 26.45 (-7.45%)
IMCR : 28.26 (-3.88%)
CSTL : 26.52 (-5.76%)
SPRO : 0.9948 (-3.88%)
Beam Therapeutics Reports Successful Preclinical Data on CD117 mAb Conditioning for Base-Edited Hematopoietic Stem Cell Therapy

Beam Therapeutics announced successful long-term engraftment of base-edited stem cells using anti-CD117 mAb conditioning in preclinical studies.Quiver AI SummaryBeam Therapeutics has announced promising...

BEAM : 26.45 (-7.45%)
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

BEAM : 26.45 (-7.45%)
Beam Therapeutics Reports Promising Results from BEACON Phase 1/2 Trial of BEAM-101 for Severe Sickle Cell Disease

All seven patients treated with BEAM-101 showed significant improvements in hemoglobin levels and resolved anemia without complications.Quiver AI SummaryBeam Therapeutics announced promising results from...

BEAM : 26.45 (-7.45%)
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

BEAM : 26.45 (-7.45%)
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer

Beam Therapeutics appoints Sravan K. Emany as CFO to enhance financial strategy and support genetic medicine advancements.Quiver AI SummaryBeam Therapeutics Inc. has announced the appointment of Sravan...

BEAM : 26.45 (-7.45%)
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

BEAM : 26.45 (-7.45%)
Beam Therapeutics Appoints Chirfi Guindo of Merck to Board of Directors

Beam Therapeutics appoints Chirfi Guindo, former Merck executive, to its board of directors to enhance strategic growth initiatives.Quiver AI SummaryBeam Therapeutics Inc. has appointed Chirfi Guindo,...

BEAM : 26.45 (-7.45%)
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

BEAM : 26.45 (-7.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 31.85
2nd Resistance Point 30.47
1st Resistance Point 28.46
Last Price 26.45
1st Support Level 25.07
2nd Support Level 23.69
3rd Support Level 21.68

See More

52-Week High 49.50
Fibonacci 61.8% 38.55
Fibonacci 50% 35.17
Fibonacci 38.2% 31.79
Last Price 26.45
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar